CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.68
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.955

05 Dec
2023

-0.045

OPEN

$1.96

-2.25%

HIGH

$2.06

214,987

LOW

$1.94

TARGET
$4.25 117.4% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx - 7.2 - 6.6 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A 0.0% xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.38%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.51

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-7.2
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx23.2 M
Book Value Per Share xxxxxxxxxxxxxxx39.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.7 M
Net Profit Margin xxxxxxxxxxxxxxx-28.47 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-16.61 %
Return on Invested Capital xxxxxxxxxxxxxxx-15.02 %
Return on Assets xxxxxxxxxxxxxxx-12.56 %
Return on Equity xxxxxxxxxxxxxxx-16.61 %
Return on Total Capital xxxxxxxxxxxxxxx-16.46 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx20 M
Price To Book Value xxxxxxxxxxxxxxx2.98

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx1.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.67 %
Cost of Goods Sold xxxxxxxxxxxxxxx17 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx3 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

06/12/2023

1

Speculative Buy

$4.25

117.39%

Tier 1 academic hospital in the US, Duke, has become the first US client for Cyclopharm, highlights Bell Potter, having signed a contract to use Technegas. Formerly, Duke had participated in the company’s clinical trial.

Management had previously logged 420 individual expressions of interest for Technegas, and is currently working through contract negotiations, notes the broker. It's expected most contracts (including Duke) will be for multiple Technegas generators.

The $4.25 target and Speculative Buy rating are unchanged.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 1.00 cents and EPS of minus -6.60 cents.
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of minus -2.50 cents.
Access Stockbroker Research History >

CYC STOCK CHART

FNArena News on CYC

1
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
2
FNArena Corporate Results Monitor – 24-08-2023

Aug 24 2023 - Australia
3
Weekly Ratings, Targets, Forecast Changes – 28-04-23

May 01 2023 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Mar 06, 2023

Mar 06 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jul 21, 2022

Jul 21 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest